DES daughters
DES Daughters refers to the female offspring of women who were prescribed the synthetic estrogen Diethylstilbestrol (DES) during pregnancy. DES was widely used between the early 1940s and the late 1970s with the intention of preventing miscarriage, premature labor, and related complications of pregnancy. However, it was later discovered that exposure to DES in utero could lead to a variety of health issues in the offspring, particularly in females, hence the term "DES Daughters."
Health Effects[edit | edit source]
Research has identified several health effects associated with DES exposure among daughters of women who took the drug during pregnancy. These include, but are not limited to:
- Clear Cell Adenocarcinoma (CCA): A rare type of vaginal and cervical cancer found in DES daughters, significantly higher than in the unexposed population.
- Reproductive Tract Anomalies: Structural changes in the reproductive organs, such as T-shaped uterus, which can lead to fertility issues and poor pregnancy outcomes.
- Increased Risk of Breast Cancer: Studies have shown that women exposed to DES in utero have a slightly increased risk of developing breast cancer after the age of 40 compared to the unexposed population.
- DES-Related High-Risk Pregnancy: DES daughters are at a higher risk of experiencing ectopic pregnancy, preterm delivery, and miscarriage.
Legal and Social Impact[edit | edit source]
The discovery of the adverse effects of DES led to a series of legal battles, with many DES daughters and their families seeking compensation for the harm caused. These cases highlighted the importance of drug safety and the need for rigorous testing before market approval. The DES tragedy also spurred changes in pharmaceutical regulations and contributed to the development of patient advocacy movements.
Current Recommendations[edit | edit source]
Medical professionals recommend that DES daughters undergo specialized healthcare monitoring, including regular gynecological exams and mammograms. Awareness and education about the potential health risks are also crucial for managing the long-term effects of DES exposure.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
